[style=color: #1a0dab;][PDF][/style] MP85-13 ERECTILE FUNCTION IN 478 HYPOGONADAL [style=font-weight: bold;]MEN[/style]WITH MODERATE TO SEVERE ED WITH AND WITHOUT [style=font-weight: bold;]TESTOSTERONE[/style]THERAPY FOR UP TO …
[style=color: #006621;]A Haider, KS Haider, G Doros, A Traish - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS 478 men[/style]with [style=font-weight: bold;]testosterone[/style]? 350 ng/dL and hypogonadal symptoms had
moderate to severe ED according to IIEF-EF (5+ 1, maximum score: 30). 246
received [style=font-weight: bold;]testosterone[/style]undecanoate injections (TU) 1000 mg/12 weeks following an …
[style=color: #1a0dab;][PDF][/style] MP85-15 [style=font-weight: bold;]TESTOSTERONE[/style]TREATMENT IN [style=font-weight: bold;]MEN[/style]WITH CLASSICAL VS FUNCTIONAL HYPOGONADISM: RESULTS FROM A 9-YEAR-REGISTRY
[style=color: #006621;]M Zitzmann, E Nieschlag, A Traish, S Kliesch - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS Registry data of max. 9 years comprising 650 patients with
hypogonadism including 266 men[/style]with primary (mean age 34.0±11.7 years), 196
with secondary (mean age 31.9±12.0 years) and 188 with functional hypogonadism …
[style=color: #1a0dab;][PDF][/style] PD62-05 BRIDGING THE GAP BETWEEN LOW [style=font-weight: bold;]TESTOSTERONE[/style]AND PROSTATE INFLAMMATION IN HYPOGONADAL [style=font-weight: bold;]MEN[/style]
[style=color: #006621;]A Gabrielson, A Reddy, A Sholl, L Alzweri… - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS Twenty prostate specimens from patients (10 hypogonadal, 10
eugonadal) were stained for p65 (NF-? B) and TGF-? receptor (TGF-?R) expression.
Patients were stratified by pre-RP testosterone[/style]:< 300 ng/dL as hypogonadal,> 400 …
[style=color: #1a0dab;][PDF][/style] MP85-14 VARIANCE IN PEAK AND TROUGH [style=font-weight: bold;]TESTOSTERONE[/style]LEVELS IN [style=font-weight: bold;]MEN[/style]USING INTRAMUSCULAR [style=font-weight: bold;]TESTOSTERONE[/style]
[style=color: #006621;]B Nascimento, HL Bernie, E Schofield, JP Mulhall - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS Patients with 3 consecutive Tp and Tt levels available, while on a stable
dose and interval of IM T cypionate were analyzed. All patients were instructed as
follows: Tp levels to checked 18 hours after IM T injection, and Tt levels to be drawn …[/style]
MP85-06 TOREMIFENE CITRATE IMPROVES HIGH-DENSITY LIPOPROTEIN LEVELS IN [style=font-weight: bold;]MEN[/style]ON [style=font-weight: bold;]TESTOSTERONE[/style]REPLACEMENT THERAPY
[style=color: #006621;]DJ Mazur, TP Kohn, A Perez-Orozco, JA McBride… - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS Men[/style]on TTh with low HDL levels (< 39 mg/dL) at a single andrology clinic
treated between October 2015 and August 2017 with either toremifine (60 mg daily),
niacin (titrated to 1,000 mg daily over 2 months) plus krill oil (1,000 mg daily)(NKO) …
MP80-20 USE OF NON-[style=font-weight: bold;]TESTOSTERONE[/style]BASED HORMONE THERAPIES AMONG PRIVATELY INSURED US [style=font-weight: bold;]MEN[/style], 2009-2015
[style=color: #006621;]M Henry, D Patil, A Nangia, A Mehta - The Journal of Urology, 2018[/style]
[style=font-family: arial;]METHODS We used 2009-2015 Truven Health MarketScan Data to identify men[/style]
using T & non-T hormone therapies (clomiphene citrate, aromatase inhibitors, human
chorionic gonadotropin (hCG), & follicle stimulating hormone (FSH)), using National.
